Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Completed · Phase 1
Conditions studied: KRAS Mutant Metastatic Colorectal Cancer
In brief
This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.
Key facts
- Study ID
- NCT01274624
- Run by
- Oncolytics Biotech
- People needed
- 36
- Starts
- 2010-12-01
- Expected to finish
- 2018-11-01
- Last updated by the study team
- 2018-12-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- New York Presbyterian Hospital/ Weill Cornell Medical College — New York, New York, United States
- Montefiore Medical Center/Albert Einstein College of Medicine — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.